Ying Huang, chief executive officer, Legend Biotech, discussed new data from the CARTIFAN-1 and CARTITUDE-2 studies.
“In cohort B, we enrolled patients who have been treated with the standard of care frontline therapy, such as bone marrow transplant, or... standard cocktail therapies... but unfortunately, these patients relapsed within 12 months of that initiation of therapy. These patients havevery poor prognosis because if a patient relapses so early after frontline therapy, the median survival is only about 26 months, unfortunately. So, this patient population needs a new therapy.”
New data on the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; Legend Biotech), approved for the fifth line treatment of multiple myeloma, were presented in 3 posters at the 64th American Society of Hematology (ASH) Annual Meeting, held December 10-12, 2022, in New Orleans, Louisiana.
CGTLive spoke with Ying Huang, chief executive officer, Legend Biotech, to learn more about the new data from the CARTITUDE-2 (NCT04133636) and CARTIFAN-1 (NCT03758417) studies. He discussed the positive data seen in second-line treatment of patients with early relapsed disease as well as longer follow-up data in patients treated in the fifth line.